Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
The Swiss group picks up Spark Therapeutics for $4.8bn, marking the biggest gene therapy buyout since Novartis’s $8.7bn move on Avexis.
In the race to develop a haemophilia B gene therapy Uniqure now has the upper hand.
Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…